Rob B Van Der Luijt

List of Publications by Citations

24 papers	2,298 citations	16 h-index	24 g-index
24 ext. papers	2,946 ext. citations	12.7 avg, IF	2.34 L-index

#	Paper	IF	Citations
24	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
23	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
22	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
21	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
20	Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. *Nature Biotechnology*, **2014**, 32, 1019-25	44.5	152
19	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80
18	MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. *BMC Medicine*, **2016**, 14, 182	11.4	65
17	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
16	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. *Journal of Medical Genetics*, **2018**, 55, 15-20	5.8	36
15	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
14	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
13	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. *Journal of Medical Genetics*, **2015**, 52, 224-30	5.8	28
12	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
11	Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial. *Genetics in Medicine*, **2016**, 18, 137-44	8.1	24
10	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
9	Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. *BMC Cancer*, **2011**, 11, 6	4.8	20
8	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16

7	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
6	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
5	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. *Familial Cancer*, **2016**, 15, 607-16	3	10
4	Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. *European Journal of Endocrinology*, **2019**, 180, K15-K19	6.5	10
3	Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands. *Familial Cancer*, **2017**, 16, 271-277	3	9
2	The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?. *European Journal of Human Genetics*, **2018**, 26, 848-857	5.3	4
1	Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences. *Hereditary Cancer in Clinical Practice*, **2021**, 19, 9	2.3	0